Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

RVMD

+ Watchlist+ Portfolio

Revolution Medicines, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$162.69
52-Week Range
$69.50 – $224.31
Market Cap
$34.57B
P/E (TTM)
—
EPS (TTM)
-9.13
Dividend Yield
0.00%
Advanced Metrics
Price/Book
14.39
PEG Ratio
—
Return on Equity
-93.56%
Return on Assets
-32.13%
Gross Margin
0.00%
Operating Margin
-852.98%
Profit Margin
0.00%
Current Ratio
8.36
Debt/Equity
0.50
Total Debt
$1.21B
Free Cash Flow
$-886.29M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$32.13B

Market Snapshot

About

Revolution Medicines, Inc. is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The company focuses on creating innovative small molecule drugs that address difficult-to-treat cancers driven by RAS mutations, one of the most common oncogenic drivers. Revolution Medicines utilizes a structure-based drug design platform to advance multiple programs through clinical development.